Antitumor activity of DAB389 IL-2 fusion toxin in mycosis fungoides
- 1 July 1998
- journal article
- clinical trial
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 39 (1) , 63-73
- https://doi.org/10.1016/s0190-9622(98)70403-7
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Treatment of mycosis fungoides with photochemotherapy (PUVA): Long-term follow-upJournal of the American Academy of Dermatology, 1995
- DAB486IL‐2 fusion toxin in refractory rheumatoid arthritisArthritis & Rheumatism, 1993
- Interleukin 2 receptor‐targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin‐related interleukin 2 fusion protein into cellsEuropean Journal of Immunology, 1990
- A Randomized Trial Comparing Combination Electron-Beam Radiation and Chemotherapy with Topical Therapy in the Initial Treatment of Mycosis FungoidesNew England Journal of Medicine, 1989
- Comparative study of systemic interferon alfa-nl and isotretinoin in the treatment of resistant condylomata acuminataJournal of the American Academy of Dermatology, 1989
- Interferon alfa-2a in the treatment of cutaneous T cell lymphomaJournal of the American Academy of Dermatology, 1989
- An anti‐CD5 immunotoxin for chronic lymphocytic leukemia: Enhancement of cytotoxicity with human serum albumin‐monensinInternational Journal of Cancer, 1989
- Photochemotherapy in cutaneous T cell lymphoma and parapsoriasis en plaquesJournal of the American Academy of Dermatology, 1985
- Monoclonal antibody analysis of diphtheria toxin—I. Localization of epitopes and neutralization of cytotoxicityMolecular Immunology, 1984
- T cell growth factor receptors. Quantitation, specificity, and biological relevanceThe Journal of Experimental Medicine, 1981